Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Option chain shows key data for Neurogene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Neurogene (NGNE, Beatty) is slated to release initial clinical data from its NGN-401 study on Monday (NASDAQ:MNDY), November 11. Despite recent market pressures on Taysha's shares due to pre-data ...

NEW YORK - Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company focused on developing genetic treatments for rare neurological diseases, has announced an agreement for a private investment in ...

Company to host webcast to review interim clinical data from Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome on November 11 at 4:30 p.m. ET Neurogene Inc. (Nasdaq: NGNE), a clinical-stage ...